European heart health survey 2019.
aortic stenosis
awareness
heart valve disease
knowledge
survey
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
07
08
2020
revised:
28
09
2020
accepted:
30
09
2020
pubmed:
29
10
2020
medline:
10
8
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
Rising life expectancy in the western population is increasing the prevalence of heart valve diseases (HVD). The level of awareness and initial screening for HVD should be sufficient. The potential impact of HVD on the daily activities of the elderly population in Europe might affect our society. A survey was conducted, including a total of 12 832 people aged ≥ 60 years in 11 European countries. Of all the people surveyed, 5.6% could correctly describe aortic valve stenosis. Most participants (75.0%) claimed they regularly do activities like sports or social activities, 29.2% provide care for a family member, friend or acquaintance. The majority (69.2%) would be prevented from doing these activities by symptoms such as chest pain, fatigue or shortness of breath. Having chest pain (76.5%) and shortness of breath (57.8%) were reasons for most people to arrange an appointment with their GP, whereas only 26.2% would visit a GP for fatigue. 67.6% of respondents claimed to be checked with a stethoscope by their GP occasionally, never, or only when they ask. The preferred treatment option for HVD is a keyhole procedure (45.8%), whereas open heart surgery would only be preferred by 7.0%. Knowledge about HVD is still low. Neither appointments with a GP driven by symptoms nor regular use of a stethoscope are a reliable guarantee for early diagnosis. With the over 60s in Europe playing an active role in social life, awareness campaigns and regular heart health checks may guarantee early diagnosis and treatment of HVD.
Sections du résumé
BACKGROUND
BACKGROUND
Rising life expectancy in the western population is increasing the prevalence of heart valve diseases (HVD).
HYPOTHESIS
OBJECTIVE
The level of awareness and initial screening for HVD should be sufficient. The potential impact of HVD on the daily activities of the elderly population in Europe might affect our society.
METHODS AND RESULTS
RESULTS
A survey was conducted, including a total of 12 832 people aged ≥ 60 years in 11 European countries. Of all the people surveyed, 5.6% could correctly describe aortic valve stenosis. Most participants (75.0%) claimed they regularly do activities like sports or social activities, 29.2% provide care for a family member, friend or acquaintance. The majority (69.2%) would be prevented from doing these activities by symptoms such as chest pain, fatigue or shortness of breath. Having chest pain (76.5%) and shortness of breath (57.8%) were reasons for most people to arrange an appointment with their GP, whereas only 26.2% would visit a GP for fatigue. 67.6% of respondents claimed to be checked with a stethoscope by their GP occasionally, never, or only when they ask. The preferred treatment option for HVD is a keyhole procedure (45.8%), whereas open heart surgery would only be preferred by 7.0%.
CONCLUSION
CONCLUSIONS
Knowledge about HVD is still low. Neither appointments with a GP driven by symptoms nor regular use of a stethoscope are a reliable guarantee for early diagnosis. With the over 60s in Europe playing an active role in social life, awareness campaigns and regular heart health checks may guarantee early diagnosis and treatment of HVD.
Identifiants
pubmed: 33111998
doi: 10.1002/clc.23478
pmc: PMC7724240
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1539-1546Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Références
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Am Coll Cardiol. 2004 Feb 4;43(3):405-9
pubmed: 15013122
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Circulation. 1968 Jul;38(1 Suppl):61-7
pubmed: 4894151
EuroIntervention. 2018 Jun 08;14(3):e264-e271
pubmed: 29599103
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219
EuroIntervention. 2016 Sep 18;12(7):883-9
pubmed: 27283409
Circulation. 1997 May 6;95(9):2262-70
pubmed: 9142003
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Clin Cardiol. 2020 Dec;43(12):1539-1546
pubmed: 33111998
Eur Heart J. 2013 Jun;34(21):1538-47
pubmed: 23111418
Clin Res Cardiol. 2020 May;109(5):611-615
pubmed: 31573055
Am J Cardiol. 2015 May 15;115(10):1443-7
pubmed: 25784513
EuroIntervention. 2018 Jul 20;14(4):e390-e396
pubmed: 29741488
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
Eur Heart J. 2018 Feb 21;39(8):667-675
pubmed: 29228149
Lancet. 2017 Aug 19;390(10096):773-780
pubmed: 28831993
Am J Cardiol. 1999 Mar 15;83(6):897-902
pubmed: 10190406
Eur Heart J. 2016 Feb 21;37(8):703-12
pubmed: 26614824
EuroIntervention. 2018 May 20;14(1):41-49
pubmed: 29581084
Circulation. 2017 May 9;135(19):1802-1814
pubmed: 28336788
BMJ Open. 2017 Jan 27;7(1):e012240
pubmed: 28131996
N Engl J Med. 2001 Jan 18;344(3):227; author reply 228-9
pubmed: 11188839
Clin Res Cardiol. 2019 Jan;108(1):61-67
pubmed: 29943272
PLoS One. 2019 Sep 26;14(9):e0222979
pubmed: 31557200